CLDX Celldex Therapeutics Inc

Price (delayed)

$27.11

Market cap

$1.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.86

Enterprise value

$1.01B

Sector: Healthcare
Industry: Biotechnology

Highlights

CLDX's EPS is up by 36% YoY and by 8% from the previous quarter
The debt has decreased by 17% YoY and by 10% QoQ
Celldex Therapeutics's equity has soared by 132% YoY but it has decreased by 7% from the previous quarter
CLDX's quick ratio has surged by 109% year-on-year but it is down by 24% since the previous quarter
Celldex Therapeutics's net income has decreased by 38% YoY and by 7% from the previous quarter

Key stats

What are the main financial stats of CLDX
Market
Shares outstanding
39.61M
Market cap
$1.07B
Enterprise value
$1.01B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.53
Price to sales (P/S)
199.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
187.53
Earnings
Revenue
$5.37M
EBIT
-$64.86M
EBITDA
-$61.32M
Free cash flow
-$48.18M
Per share
EPS
-$1.86
Free cash flow per share
-$1.22
Book value per share
$4.9
Revenue per share
$0.14
TBVPS
$4.76
Balance sheet
Total assets
$219.07M
Total liabilities
$24.9M
Debt
$3.14M
Equity
$194.17M
Working capital
$164.52M
Liquidity
Debt to equity
0.02
Current ratio
10.69
Quick ratio
10.48
Net debt/EBITDA
1.08
Margins
EBITDA margin
-1,141.1%
Gross margin
100%
Net margin
-1,185.2%
Operating margin
-1,323%
Efficiency
Return on assets
-26.2%
Return on equity
-29.2%
Return on invested capital
-44.7%
Return on capital employed
-32.1%
Return on sales
-1,206.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
8.4%
1 week
-0.73%
1 month
21.73%
1 year
1,104.89%
YTD
54.74%
QTD
31.6%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$5.37M
Gross profit
$5.37M
Operating income
-$71.1M
Net income
-$63.69M
Gross margin
100%
Net margin
-1,185.2%
The net margin has decreased by 47% QoQ and by 25% YoY
CLDX's operating margin is down by 45% since the previous quarter and by 23% year-on-year
Celldex Therapeutics's net income has decreased by 38% YoY and by 7% from the previous quarter
Celldex Therapeutics's operating income has decreased by 35% YoY and by 5% QoQ

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
5.53
P/S
199.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
187.53
CLDX's EPS is up by 36% YoY and by 8% from the previous quarter
Celldex Therapeutics's equity has soared by 132% YoY but it has decreased by 7% from the previous quarter
The P/B is 82% higher than the last 4 quarters average of 2.8
CLDX's price to sales (P/S) is 77% higher than its last 4 quarters average of 104.0
Celldex Therapeutics's revenue has decreased by 28% from the previous quarter but it has increased by 10% YoY

Efficiency

How efficient is Celldex Therapeutics business performance
Celldex Therapeutics's ROIC has increased by 48% YoY and by 7% from the previous quarter
CLDX's ROS is down by 47% from the previous quarter and by 27% YoY
The ROE has grown by 39% YoY and by 7% from the previous quarter
The ROA is up by 28% YoY and by 5% QoQ

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
The current ratio has soared by 109% YoY but it has decreased by 23% from the previous quarter
CLDX's quick ratio has surged by 109% year-on-year but it is down by 24% since the previous quarter
The debt is 98% lower than the equity
Celldex Therapeutics's equity has soared by 132% YoY but it has decreased by 7% from the previous quarter
CLDX's debt to equity has dropped by 60% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.